Real-World data shows avelumab helps control advanced bladder cancer after chemo

NCT ID NCT05366725

Completed Disease control Sponsor: Merck Healthcare KGaA, Darmstadt, Germany, an affiliate of Merck KGaA, Darmstadt, Germany Source: ClinicalTrials.gov ↗

First seen Jun 27, 2026 · Last updated Jun 27, 2026

Summary

This study looked at 106 adults with advanced bladder cancer that hadn't gotten worse after initial chemotherapy. They received avelumab as a maintenance treatment to help keep the cancer under control. Researchers tracked how long patients lived and any side effects in real-world settings over about 4 years.

This is an AI summary of the original study and may miss details. Read our disclaimer.

Get updates

Get notified about this study

Sign up to get updates when this study changes or when new studies for LOCALLY ADVANCED OR METASTATIC UROTHELIAL CARCINOMA are added.

Our safety recommendation!

By submitting, you agree to our Terms of use

Conditions

The condition(s) this trial relates to.

urothelial carcinoma

As listed by the trial registrant

The condition terms exactly as the trial's registrant entered them.

UROTHELIAL CANCER

Contacts and locations

Show contact details

Locations

Beatson West of Scotland Cancer Centre

Glasgow, G12 0YN, United Kingdom
Churchill Hospital

Oxford, OX3 7LE, United Kingdom
Clatterbridge Hospital

Metropolitan Borough of Wirral, CH63 4JY, United Kingdom
Guy's and St Thomas' Hospital

London, SE1 9RT, United Kingdom
Lister Hospital

Stevenage, SG1 4AB, United Kingdom
Royal Preston Hospital

Preston, PR2 9HT, United Kingdom
Royal Surrey County Hospital

Guildford, GU2 7XX, United Kingdom
The Christie NHS Foundation Trust

Manchester, M20 4BX, United Kingdom
University College London Hospital

London, NW1 2PG, United Kingdom
University Hospitals Bristol

Bristol, BS1 3NU, United Kingdom

More trials for these conditions

Other studies related to the condition(s) this trial covers.